throbber
Downloaded from
`
`jpet.aspetjournals.org
`
` at ASPET Journals on August 5, 2019
`
`0022-3565/02/3011-322–332$7.00
`THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
`Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics
`JPET 301:322–332, 2002
`
`Vol. 301, No. 1
`4641/974298
`Printed in U.S.A.
`
`4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-
`1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1,3-
`thiazol-2-amine Hydrochloride (SSR125543A): A Potent and
`Selective Corticotrophin-Releasing Factor1 Receptor
`Antagonist. I. Biochemical and Pharmacological
`Characterization
`
`DANIELLE GULLY, MICHEL GESLIN, LAURENCE SERVA, EVELYNE FONTAINE, PIERRE ROGER, CHRISTINE LAIR,
`VALERIE DARRE, CLAUDINE MARCY, PIERRE-ERIC ROUBY, JACQUES SIMIAND, JOSETTE GUITARD,
`GEORGETTE GOUT, REGIS STEINBERG, DANIEL RODIER, GUY GRIEBEL, PHILIPPE SOUBRIE, MARC PASCAL,
`REBECCA PRUSS, BERNARD SCATTON, JEAN-PIERRE MAFFRAND, and GERARD LE FUR
`Exploratory Research Department, Sanofi-Synthelabo, Toulouse, France (D.G., M.G., L.S., E.F., P.R., C.L., V.D., C.M., P.E.R., M.P.) and
`Strasbourg, France (R.P.); Central Nervous System Department, Sanofi-Synthelabo, Toulouse, France (J.S., J.G., G.G.), Montpellier, France
`(R.G., D.R., P.S.), and Paris, France (G.G.); Discovery Research Division, Sanofi-Synthelabo, Paris, France (B.S., J.P.M., G.L.F.)
`Received October 11, 2001; accepted December 31, 2001
`This article is available online at http://jpet.aspetjournals.org
`
`ABSTRACT
`4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-
`(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1,3-thia-
`zol-2-amine hydrochloride (SSR125543A), a new 2-aminothiazole
`derivative, shows nanomolar affinity for human cloned or native
`corticotrophin-releasing factor (CRF)1 receptors (pKi values of
`8.73 and 9.08, respectively), and a 1000-fold selectivity for CRF1
`versus CRF2␣ receptor and CRF binding protein. SSR125543A
`antagonizes CRF-induced stimulation of cAMP synthesis in hu-
`man retinoblastoma Y 79 cells (IC50 ⫽ 3.0 ⫾ 0.4 nM) and adre-
`nocorticotropin hormone (ACTH) secretion in mouse pituitary tu-
`mor AtT-20 cells. SSR125543A is devoid of agonist activity in
`these models. Its brain penetration was demonstrated in rats by
`using an ex vivo [125I-Tyr0] ovine CRF binding assay. SSR125543A
`displaced radioligand binding to the CRF1 receptor in the brain
`
`(duration of action ⬎24 h).
`with an ID50 of 6.5 mg/kg p.o.
`SSR125543A also inhibited the increase in plasma ACTH levels
`elicited in rats by i.v. CRF (4 ␮g/kg) injection (ID50 ⫽ 1, 5, or 5
`mg/kg i.v., i.p., and p.o., respectively); this effect lasted for more
`than 6 h when the drug was given orally at a dose of 30 mg/kg.
`SSR125543A (10 mg/kg p.o.) reduced by 73% the increase in
`plasma ACTH levels elicited by a 15-min restraint stress in rats.
`Moreover, SSR125543A (20 mg/kg i.p.) also antagonized the in-
`crease of hippocampal acetylcholine release induced by i.c.v.
`injection of 1 ␮g of CRF in rats. Finally, SSR125543A reduced
`forepaw treading induced by i.c.v. injection of 1 ␮g of CRF in
`gerbils (ID50 ⫽ ⬃10 mg/kg p.o.). Altogether, these data indicate
`that SSR125543A is a potent, selective, and orally active CRF1
`receptor antagonist.
`
`Corticotrophin-releasing factor (CRF) is the prime coordi-
`nator of the neuroendocrine and behavioral responses to
`stress (Owens and Nemeroff, 1991). This 41-amino acid pep-
`tide is the major hypothalamic factor responsible for the
`stimulation of corticotrophin (ACTH) secretion from the an-
`terior pituitary, which in turn induces synthesis and release
`of glucocorticoids from the adrenal cortex (Vale et al., 1981).
`The highest density of CRF-containing cell bodies is found in
`the medial paraventricular nucleus of the hypothalamus, a
`brain region that projects
`to the median eminence
`
`(Sawchenko and Swanson, 1991). CRF-containing neurons
`are also found in extrahypothalamic areas, e.g., limbic struc-
`tures (Gray and Bingaman, 1996), suggesting that CRF may
`also play a neurotransmitter role, mediating both stress re-
`sponse and affective behavior (Arborelius et al., 1999). Be-
`cause CRF hypersecretion associated with overactivation of
`the hypothalamo-pituitary-adrenal (HPA) axis has been im-
`plicated in depression and anxiety, the discovery of nonpep-
`tide molecules that selectively inhibit CRF activity is of ma-
`jor clinical interest (Holsboer, 1999).
`
`ABBREVIATIONS: CRF, corticotropin-releasing factor; ACTH, adrenocorticotropin hormone; HPA, hypothalomo-pituitary-adrenal axis; CRF-BP,
`corticotropin-releasing factor-binding protein; DMSO, dimethyl sulfoxide; CHO, Chinese hamster ovary; PBS, phosphate-buffered saline; ANOVA,
`analysis of variance; ACh, acetylcholine; R-121919, 3-[6-(dimethylamino)-4-methyl-pyrid-3-yl]-2,5-dimethyl-N,N-dipropyl-pyrazolo[2,3-a]pyrimi-
`din-7-amine; antalarmin, butylethyl-[2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-amine.
`
`322
`
`1
`
`NEUROCRINE 1020
`
`

`

`SSR125543A, a New Nonpeptide CRF1 Receptor Antagonist
`
`323
`
`Downloaded from
`
`jpet.aspetjournals.org
`
` at ASPET Journals on August 5, 2019
`
`possess pharmacological activity in experimental models of
`anxiety after oral administration in the 3- to 30-mg/kg
`range (Gutman et al., 2000). Beneficial effects of this com-
`pound have been observed in an open clinical trial per-
`formed in depressed patients, supporting the view that
`CRF1 receptor antagonism could be of therapeutic value in
`the treatment of depression. However R-121919’s develop-
`ment has been stopped because of hepatic toxicity (Zobel et
`al., 2000). In the present study, we report on the charac-
`terization of a new CRF1 receptor antagonist, 4-(2-
`chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-
`1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propy-
`nyl)-1,3-thiazol-2-amine hydrochloride (SSR125543A), ob-
`tained by the optimization of a lead compound discovered
`by random screening of several thousand chemicals. This
`compound belongs to the novel 2-aminothiazole chemical
`family (Fig. 1).
`
`Experimental Procedures
`
`Animals
`Male Sprague-Dawley CD rats and female OF1 mice purchased
`from Iffa Credo (L’Arbresele, France), and male Mongolian gerbils
`from Janvier (Le Genest St. Isle, France) were housed in a controlled
`temperature and light-dark environment with water and chow avail-
`able ad libitum before the experiments. All experimental procedures
`were approved by the Animal Care and Use Committee of Sanofi-
`Synthelabo Recherche and were carried out in accordance with
`French legislation.
`
`Materials
`SSR125543A (Fig. 1) and antalarmin were synthesized by Sanofi-
`Synthelabo Recherche (Toulouse, France). Both compounds were
`solubilized in pure DMSO for the in vitro assays and in 5% DMSO
`and 5% Cremophor EL in saline when administered to mouse, rat,
`and gerbil. Rat/human CRF, ovine CRF, [D-Phe11,His12]Svg(11– 40)
`(antisauvagine-30), and rat/human CRF(6 –33)
`from Neosystem
`(Strasbourg, France) were solubilized in 0.1% acetic acid solution
`containing 1 mg/ml serum bovine albumin. [125I-Tyr0] ovine CRF,
`[125I-Tyr0] rat/human CRF, and [125I-Tyr0] sauvagine were pur-
`chased from PerkinElmer Life Sciences (Boston, MA). Cell culture
`media, antibiotics, and fetal calf serum were obtained from Invitro-
`
`Fig. 1. Chemical structure of the selective CRF1 receptor antagonist
`SSR125543A.
`
`The functional effects of CRF are mediated via the activa-
`tion of two receptor subtypes, CRF1 and CRF2, that are 70%
`homologous in their amino acid sequences but appear phar-
`macologically and anatomically distinct. Both receptor sub-
`types are members of the G protein-coupled receptor super-
`family positively coupled to adenylate cyclase. CRF1 is the
`predominant receptor within the pituitary, cerebellum, and
`neocortex. Two CRF2 isoforms exist: the CRF2␣, which is
`expressed in limbic regions, e.g., lateral septum and dorsal
`raphe nucleus; and the CRF2␤, more abundant in the periph-
`ery (Chalmers et al., 1995). Moreover, a CRF binding protein
`(CRF-BP) binds native rat/human CRF with higher affinity
`than CRF receptors (Behan et al., 1995). CRF-BP is ex-
`pressed in the brain of numerous species, where it might
`regulate CRF-mediated neurotransmission.
`A second CRF receptor endogenous agonist, urocortin, has
`been described (45% homology with CRF) and binds to CRF2
`receptors with a 10-fold higher affinity than CRF. Urocortin
`mRNA expression is prominent in the Edinger-Westphal nu-
`cleus, which does not contain CRF mRNA and is colocalized
`with the CRF2␣ receptor mRNA in the rat lateral septum and
`dorsal raphe nucleus (Vaughan et al., 1995). Recently, uro-
`cortin II, which possesses only 26% homology with CRF, has
`been cloned and found to be a selective agonist at CRF2
`receptors (Reyes et al., 2001).
`The hypothesis that CRF plays a role in the pathophysiol-
`ogy of affective disorders has been put forward on the basis of
`experimental behavioral data, and is consistent with the
`contribution of CRF system alterations to the etiology of
`psychiatric disorders exacerbated or precipitated by stress.
`Thus, high levels of cerebrospinal fluid CRF and an increased
`number of CRF immunoreactive neurons in the hypotha-
`lamic paraventricular nucleus have been measured in pa-
`tients with depressive disorders (Nemeroff et al., 1984). After
`electroconvulsive therapy or antidepressant treatment, HPA
`axis and CRF function normalize, suggesting that CRF over-
`activity may be a marker for human depression (Nemeroff et
`al., 1991). Moreover, intra-amygdala injection of antisense
`oligonucleotides directed against the CRF1 and CRF2 recep-
`tor mRNA in the rat and knock out of the CRF1 receptor gene
`in mice have been associated with reduced levels of anxiety
`and lower anxiogenic responses to i.v. CRF injections (Lieb-
`sch et al., 1995; Heinrichs et al., 1997; Smagin and Dunn,
`2000). Furthermore, CRF1 receptor antagonists have demon-
`strated anxiogenic effects in rodents (Gutman et al., 2000).
`A number of synthetic CRF1 receptor antagonists have
`been identified (Gutman et al., 2000), e.g., butylethyl-[2,5-
`dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimi-
`din-4-yl]-amine (CP-154,526), 5-chloro-N-cyclopropylmethyl-
`2-methyl-N-propyl-N⬘-(2,4,6-trichlorophenyl)-pyrimidin-4,6-
`diamine (NBI 27914), 4-(3-pentylamino)-2,7-dimethyl-8-(2-
`methyl-4-methoxyphenyl)-pyrazolo-[1,5-a ]pyrimidine
`(DMP904), 2-[(N -(2-methylthio-4-isopropylphenyl)-N -
`ethylamino]-4-[4-(3-fluorophenyl)-1,2,3,6-tetrahydropyri-
`din-1-yl)-6-methylpyrimidine (CRA 1000), and R-121919
`(formerly NBI 30775). However, it is of interest to note
`that these molecules have close structural similarities,
`including pyrrolo-, pyrazolo-, and other substituted pyrim-
`idine moieties. The more recent compounds offer better
`solubility and central nervous system penetration than
`their predecessors. For example, R-121919 (Ki value of 3
`nM for the human CRF1 receptor) has been shown to
`
`2
`
`

`

`Downloaded from
`
`jpet.aspetjournals.org
`
` at ASPET Journals on August 5, 2019
`
`324
`
`Gully et al.
`
`gen (Cergy Pontoise, France). All other chemicals were from com-
`mercial sources.
`
`(BBN Software Product Corporation, Cambridge, MA) and an inter-
`nal computerized interactive procedure.
`
`Cell Cultures
`CHO cells stably transfected with the human CRF1 receptor
`(hCRF1-CHO cells) or with the human CRF2␣ receptor (hCRF2␣-CHO
`cells) were cultured in Dulbecco’s modified Eagle’s medium supple-
`mented with 10% heat inactivated fetal calf serum, 300 ␮g/ml L-
`glutamine, nonessential amino acids, 100 U/ml penicillin, 100 ␮g/ml
`streptomycin, and 0.17 ␮g/ml amphothericine. Y 79 cells purchased
`from American Type Culture Collection (Rockville, MD) were cul-
`tured in RPMI-1640 medium supplemented with 10% heat-inacti-
`vated fetal calf serum and 300 ␮g/ml L-glutamine.
`AtT-20 cells purchased from American Type Culture Collection
`were cultured in Dulbecco’s modified Eagle’s medium containing
`only in supplement 10% fetal calf serum, 300 ␮g/ml L-glutamine,
`HEPES, and sodium pyruvate. Cells were incubated at 37°C in a
`humidified atmosphere with 5% CO2 except AtT-20, which was in-
`cubated with 15% CO2.
`
`Preparation of Cell Membrane Homogenates
`Cells were cultured to confluence and the flasks were washed with
`10 ml of phosphate-buffered saline (PBS) medium and filled with an
`equal volume of PBS medium. Cells (hCRF1-CHO, hCRF2␣-CHO,
`and AtT-20) were detached from the flask with a cell scraper. Y 79
`cells were cultured in suspension. After centrifugation at 800g for 5
`min, the cell pellet was homogenized at 4°C by using a Polytron
`(setting 6, 2 ⫻ 20 s) in 50 mM Tris-HCl pH 7.4, 2 mM EDTA buffer
`for hCRF1-CHO and hCRF2␣-CHO cells. Homogenization was per-
`formed in 50 mM Tris-HCl pH 7.2, 10 mM MgCl2, 2 mM EDTA, 0.1%
`serum bovine albumin, 8 mg/l aprotinin, and 0.5 mg/ml soybean
`trypsin inhibitor for Y 79 cells. After centrifugation at 40,000g for 20
`min at 4°C, the pellet was homogenized at 4°C by using a Polytron in
`binding buffer (see below). Aliquots obtained from the membrane
`suspension were stored in liquid nitrogen.
`
`Preparation of Brain Membrane Homogenates
`Because the in vivo pharmacological profile of the compound was
`to be characterized in rodents, the inhibitory effects of SSR125543A
`on [125I-Tyr0] ovine CRF binding to rat, mouse, and gerbil brain were
`assessed.
`Mouse, rat, and gerbil were sacrificed by decapitation and brains
`were rapidly removed and homogenized at 4°C by using a Polytron
`(setting 4, 30 s) in 50 mM Tris-HCl pH 7.4, 2 mM EDTA buffer. After
`centrifugation at 40,000g for 20 min at 4°C, the 0.5-mg/ml pellet was
`homogenized at 4°C by using a Polytron in binding buffer (see below).
`Aliquots obtained from the membrane suspension were stored were
`stored at ⫺80°C.
`
`CRF1 Receptor Binding Assay
`[125I-Tyr0] ovine CRF binding was performed with hCRF1-CHO
`cell membranes, Y 79 cell membranes, or rodent brain membrane
`homogenates in the presence of 25 pM radiolabeled CRF in 50 mM
`Tris-HCl pH 7.2, 10 mM MgCl2, 2 mM EDTA, 0.1% serum bovine
`albumin, 8 mg/l aprotinin, and 0.5 mg/ml soybean trypsin inhibitor
`under a final volume of 400 ␮l. Nonspecific binding was determined
`in the presence of 1 ␮M rat/human CRF. Agonists and antagonists
`were added in 1% DMSO (final concentration). After incubation at
`20°C for 2 h, the incubation mixture was filtered on Whatman GF/B
`filters presoaked in 0.5% bovine serum albumin solution for 2 h. The
`filters were washed twice with ice-cold Tris-HCl pH 7.2 buffer and
`the radioactivity was determined with a gamma scintillation counter
`(LKB 1261 multi gamma; EG G Instruments, Evry, France). Specific
`binding was determined as the difference between total and nonspe-
`cific binding. IC50 values were determined using a nonlinear least-
`square regression analysis (Munson and Rodbard, 1980) with RS/1
`
`CRF2 Receptor Binding Assay
`[125I-Tyr0] sauvagine binding was performed using a similar pro-
`tocol as with [125I-Tyr0] ovine CRF binding. In this case, hCRF2␣-
`CHO cell membranes were used at the concentration of 2.5 ␮g of
`protein/tube in presence of 20 pM radiolabeled sauvagine, under a
`final volume of 250 ␮l. Nonspecific binding was determined in pres-
`ence of 1 ␮M unlabeled sauvagine.
`
`CRF-BP Binding Assay
`Displacement of CRF from CRF-BP was measured by a detergent
`phase separation assay. Recombinant human CRF-BP was incu-
`bated at 20°C for 2 h with 30 pM [125I-Tyr0] rat/human CRF in 0.02%
`Nonidet-40 phosphate-buffered saline, pH 7.4. Bound and free CRF
`were then separated by the addition of Triton X-114 (octylphenoxy-
`polyethoxyethanol) buffer stirring and incubation 20 min at 37°C.
`Free CRF segregates to the detergent phase at the bottom of the
`tube, and the CRF/CRF-BP complex remains in the aqueous phase.
`The amount of radioactivity in an aliquot of the aqueous phase was
`determined with a gamma scintillation counter (LKB 1261 multi
`gamma; EG G Instruments). Values were expressed as the mean ⫾
`S.E.M. of at least three determinations performed in triplicate. Spe-
`cific binding was determined as in CRF1 binding assays.
`
`Measurement of Intracellular cAMP Synthesis in Y 79
`Cells
`CRF-induced cAMP synthesis in human retinoblastoma Y 79 cells
`was assessed as described by Hauger et al. (1997). In the present
`article, two types of experiments were performed on Y 79 cells. In the
`first experiment, Y 79 cells were incubated for 15 min at 37°C under
`stirring in presence of 10 nM rat/human CRF with increasing con-
`centrations of SSR125543A in 1 mM isobutylmethyl xanthine sup-
`plemented RPMI buffer, pH 7.2. The intracellular cAMP content was
`measured after lysing the cells by 0.5% ice-cold Triton X-100 by using
`a cAMP 125I scintillation proximity assay kit (Amersham Biosciences
`plc, Little Chalfont, Buckinghamshire, UK). IC50 values were deter-
`mined using a nonlinear least-square regression analysis (Munson
`and Rodbard, 1980) with RS/1 (BBN Software Product Corporation)
`and an internal computerized interactive procedure.
`In the second experiment, Y 79 cells were incubated for 15 min at
`37°C under stirring with increasing concentrations of rat/human
`CRF alone or in presence of three concentrations of SSR125543A.
`Intracellular cAMP synthesis was expressed as the percentage of
`maximal release after subtraction of basal release. Values were
`expressed as the mean of at least three determinations performed in
`duplicate.
`
`Measurement of ACTH Secretion by AtT-20 Cells
`CRF-induced ACTH secretion in mouse pituitary AtT-20 cells was
`previously described by Litvin et al. (1984). A subclone of AtT-20/
`D16v cells was used in this study. Cells were seeded in 12-well plates
`and cultured overnight in their growth medium. They were incu-
`bated for 120 min at 37°C with 2 ml of basal medium, alone or with
`increasing concentrations of rat/human CRF in the presence or ab-
`sence of three concentrations of SSR125543A. ACTH release was
`measured on supernatant samples by using a radioimmunoassay
`(Diasorin, Stillwater, MN). Values were expressed as mean values of
`three determinations performed in triplicate.
`
`Ex Vivo Binding Assay in Rats
`SSR125543A or the corresponding vehicle was administered p.o.
`or i.v. to rats (three per group) at various doses (dose-effect studies)
`and times (time course studies) before rat decapitation and organ
`(brain and pituitary) removal. Tissues were homogenized in 10 ml of
`incubation buffer by using a Polytron (speed 21,500 rpm ⫻ 17 s) then
`
`3
`
`

`

`Downloaded from
`
`jpet.aspetjournals.org
`
` at ASPET Journals on August 5, 2019
`
`SSR125543A, a New Nonpeptide CRF1 Receptor Antagonist
`
`325
`
`diluted (1/20) with the same incubation buffer and submitted to a
`[125I-Tyr0] ovine CRF binding assay procedure as previously de-
`scribed. To determine the relative population of CRF1 binding sites
`present in crude homogenates from rat brain and pituitary, binding
`studies were performed in vitro, on naı¨ve brain and pituitary tissue.
`Competition curves were determined for ovine CRF, antisauvagine-
`30, and rat/human CRF(6 –33), two peptides selective for CRF2 recep-
`tor and CRF-BP, respectively (Behan et al., 1995; Ruhmann et al.,
`1998). In the ex vivo binding assay, nonspecific binding was defined
`with 100 nM antalarmin. Values were expressed as the mean per-
`centage of specific binding ⫾ S.E.M. Statistical differences between
`drug- and vehicle-treated groups were assessed by a Student’s t test.
`
`CRF-Induced ACTH Secretion in Rats
`Animals were habituated to the experimental procedure 1 day
`before the experiment. SSR125543A or its vehicle was administered
`p.o. or i.v. to rats (3–7/group) at various doses (dose-effect studies)
`and times (time course studies) before intravenous injection of 4
`␮g/kg rat/human CRF. Thirty minutes later, animals were sacrificed
`by decapitation and trunk blood samples were collected in a 1 mg/ml
`EDTA solution for the determination of ACTH plasma levels by
`radioimmunoassay (Diasorin). Results were expressed as the mean
`values ⫾ S.E.M. Statistical differences between drug- and vehicle-
`treated groups were assessed by a Student’s t test. The median
`inhibitory doses (ID50) with 95% confidence limits were determined
`by fitting of the dose-response curve to the four-parameter logistic
`model according to Ratkowsky and Reedy (1986). The adjustment
`was performed by nonlinear regression by using the Levenberg-
`Marquardt algorithm in the RS/1 software.
`
`Restraint Stress-Induced ACTH Secretion in Rats
`One hour after oral administration of SSR125543A or its vehicle,
`rats were placed into hemicylindrical Plexiglas enclosures (6 cm in
`width and 4 cm in height) for 15 min. After this stress period, the
`animals were placed back in their cages, carried to an adjacent room
`and immediately sacrificed. Nonstressed control animals remained
`in their cage for 15 min before sacrifice. Blood was collected in a 1
`mg/ml EDTA solution for the determination of ACTH plasma levels
`by radioimmunoassay (Diasorin). Values were expressed as the
`mean ACTH levels ⫾ S.E.M. Statistical differences between drug-
`and vehicle-treated groups were assessed by a single factor ANOVA
`or by the nonparametric Kruskall-Wallis test followed by Dunnett’s
`t test or by the Mann-Whitney U test with ␣ adjustment of Holm on
`RS1/software, respectively.
`
`CRF-Induced Hippocampal Acetylcholine Release
`Surgery and Microdialysis. Rats were anesthetized with ure-
`thane (1.4 g/kg i.p.) and then placed in a stereotaxic frame. A micro-
`dialysis probe (CMA-12, length 2 or 3 mm and outer diameter 0.5
`mm; Carnegie Medicine AB, Stockholm, Sweden) was stereotaxically
`implanted in the dorsal hippocampus. The coordinates were 3.5 mm
`posterior to bregma, 2 mm lateral to the midline, and 3.8 mm down
`from the dural surface for the hippocampus (Paxinos and Watson,
`1986). For i.c.v. injection of CRF, ejection pipettes were implanted
`into the left lateral ventricle at the following coordinates: 0.8 mm
`posterior to bregma, 1.5 mm lateral to the midline, and 3.4 mm down
`from the dural surface. The ejection of CRF (1 ␮g/2 ␮l/90 s) was
`performed by applying air pressure with a 1-ml syringe connected to
`the nontapered side of the pipette by Tygon tubing. The probes were
`perfused with a gassed Ringer’s solution containing 125 mM NaCl, 3
`mM KCl, 1.3 mM CaCl2, 1.0 mM MgCl2, 23 mM NaHCO3, and 1.5
`mM KH2PO4, pH 7.4, at a rate of 2 ␮l/min by using a microinjection
`pump (CMA-100; Carnegie Medicine AB). To reduce acetylcholine
`degradation in the dialysate, 1 ␮M neostigmine was added to the
`Ringer’s solution perfused in the hippocampal probe. Microdialysis
`sampling started 90 min after the probe was placed in the hippocam-
`pus. Serial samples were collected at 30-min intervals. SSR125543A,
`
`antalarmin, and vehicle were given intraperitoneally (5 ml/kg of
`body weight) 180 and 30 min before peptide application.
`The time course of the CRF effects was analyzed by ANOVA with
`repeated measures and Dunnett’s t test was used for individual time
`comparisons. The antagonism of the CRF effect was evaluated by
`comparing the area under the curve during the 120 min after peptide
`injection. A statistical analysis was carried out by using the Stu-
`dent’s t test.
`Assay of Acetylcholine (ACh). ACh levels were measured in
`30-min dialysate samples (50 ␮l) by using a high-performance liquid
`chromatography system (Waters, Milford, MA) as previously de-
`scribed by Steinberg et al. (1995) except for the electrochemical
`detection system (Coulochem II; ESA, Chelmsford, MA). Briefly, the
`analytical system for ACh included a trapping precolumn and im-
`mobilized enzyme reactor (BAS.MF-6151). The mobile phase, 35 mM
`phosphate buffer, pH 8.5, supplemented with the antibacterial re-
`agent Kathon (5 ml/l; BAS DF-2150), was pumped at a flow rate of
`0.8 ml/min and replaced with a fresh preparation every 3 days. The
`enzyme postcolumn reactor converted ACh to hydrogen peroxide that
`was electrochemically detected using a platinum electrode (ESA P/N
`55-0183) set at 0.3 V. The chromatographic column and enzyme
`reactor were kept at 35°C. The detection sensitivity was 0.2 pmol/50
`␮l.
`
`CRF-Induced Forepaw Treading in Gerbils
`This test was based on the observation that i.c.v. injection of CRF
`(1 ␮g/2 ␮l) produces forepaw treading (“piano playing”) in gerbils, an
`effect that is prevented by treatment with the CRF1 receptor antag-
`onist R-121919 (Owens and Nemeroff, 1999). Gerbils were placed
`individually in small transparent plastic cages for 30 min. They were
`then pretreated with SSR125543A p.o. or antalarmin i.p. CRF (1 ␮g)
`was injected i.c.v. (free-hand method; Jung et al., 1996) 15 min
`(antalarmin) or 60 min (SSR125543A) later. In each experiment, a
`control group was injected i.c.v. with the vehicle. Forepaw treading
`was measured by an observer unaware of the drug treatment, for 1
`min every 15 min over a 2-h period (8 min in total cumulative times).
`The cumulative forepaw treading time was calculated for each gerbil
`and then expressed as the mean and S.E.M. Comparisons between
`control and treated groups were performed using the Kruskall-Wal-
`lis test, followed by Mann-Whitney U test with ␣ adjustment of
`Holm.
`
`Results
`Affinity of SSR125543A for CRF1 Receptors
`SSR125543A inhibited the specific binding of [125I-Tyr0]
`ovine CRF to human CRF1 receptors expressed in CHO cells
`
`TABLE 1
`Affinity of SSR125543A for CRF receptor subtypes and for CRF1
`receptors of various species
`Values of pKi and Hill coefficients are the means ⫾ S.E.M. of three experiments
`performed in triplicate.
`
`Binding Assay
`CRF1 binding: [125I-Tyr0]ovine
`CRF ligand
`hCRF1-CHO cells
`Y 79 cells
`Rat brain
`Mouse brain
`Gerbil brain
`CRF2␣ binding: [125I-Tyr0]
`ovine sauvagine ligand
`hCRF2␣-CHO cells
`CRF-BP binding: [125I-Tyr0]
`rat/human CRF ligand
`hCRF-BP
`rCRF-BP
`
`Results
`
`pKi
`
`n
`
`1.25 ⫾ 0.10
`8.73 ⫾ 0.15
`0.97 ⫾ 0.17
`9.08 ⫾ 0.20
`0.89 ⫾ 0.12
`8.77 ⫾ 0.23
`1.16 ⫾ 0.13
`8.90 ⫾ 0.10
`0.75 ⫾ 0.11
`9.00 ⫾ 0.00
`Inhibition at 10 ␮M
`
`0%
`Inhibition at 10 ␮M
`
`0%
`0%
`
`4
`
`

`

`Downloaded from
`
`jpet.aspetjournals.org
`
` at ASPET Journals on August 5, 2019
`
`326
`
`Gully et al.
`
`with a pKi value of 8.73 ⫾ 0.15 (mean ⫾ S.E.M.; Table 1),
`which was comparable to that of antalarmin and higher than
`that of the natural ligand rat/human CRF (pKi ⫽ 8.70 and
`8.22, respectively). It also recognized with high affinity the
`native CRF1 receptors present on the human retinoblastoma
`cell line Y 79 (pKi ⫽ 9.08 ⫾ 0.20). At 10 ␮M, SSR125543A did
`not interact with the human CRF2␣ receptor expressed in
`CHO cells, or human and rat recombinant CRF-BP (Table 1).
`Binding studies performed with [125I-Tyr0] ovine CRF on
`membrane preparations obtained from rodent brains (rat,
`mouse, and gerbil) did not reveal species differences in affin-
`ity because the respective pKi values of 8.77 ⫾ 0.23, 8.90 ⫾
`0.10, and 9.00 ⫾ 0.00 were very close to the pKi for the
`human CRF1 receptor (Table 1). The high selectivity of
`SSR125543A for the CRF1 receptor was demonstrated by its
`lack of activity (inhibition lower than 50%) at 1 or 10 ␮M in
`125 assays performed by Panlabs and Cerep (receptors,
`transporters, enzymes, and ion channels) (Table 2).
`
`CRF1 Receptor Antagonism by SSR125543A: In Vitro
`Studies
`When rat/human CRF was applied to Y 79 cells, which
`express constitutively CRF1 receptors, the intracellular
`cAMP production was increased by ⬃7-fold over basal levels,
`with an EC50 value of 4.0 ⫾ 0.9 nM (mean ⫾ S.E.M).
`SSR125543A did not modify the basal level of cAMP but fully
`blocked the CRF (10 nM) response with an IC50 value of 3.0 ⫾
`0.4 nM (mean ⫾ S.E.M., n ⫽ 3; Fig. 2A). Under similar
`experimental conditions, the IC50 for antalarmin was 0.8 ⫾
`0.1 nM (mean ⫾ S.E.M., n ⫽ 3; data not shown). Increasing
`concentrations of SSR125543A produced a rightward shift of
`the rat/human CRF concentration-response curve (Fig. 2B),
`without modifying the maximal cAMP production obtained
`with rat/human CRF alone. EC50 values for CRF were 2.5 nM
`(2.1–2.9), 8.3 (5.5–12.4), 55.6 (42.5–73.0), and 92.2 (55.7–
`144.9) (means and confidence limits) in the presence or ab-
`sence of 3, 30, and 100 nM SSR125543A, respectively.
`When rat/human CRF was applied to mouse pituitary
`AtT-20 cells, which express CRF1 receptors, ACTH secretion
`was stimulated by ⬃3-fold over basal levels. SSR125543A did
`not modify basal secretion of ACTH but antagonized the
`ACTH secretion induced by increasing concentrations of rat/
`human CRF. Increasing concentrations of SSR125543A also
`produced a rightward shift of the rat/human CRF dose-re-
`sponse curve and a concentration-dependent inhibition of the
`maximal ACTH secretion elicited by rat/human CRF alone
`(Fig. 3). In the course of three experiments, EC50 values for
`CRF were 1.6 (1.4 –1.9), 11.9 (10.0 –14.1), 49.8 (34.2–74.3),
`and 128.1 (104.6 –160.0) (means and confidence limits) in the
`presence or absence of 3, 30, and 100 nM SSR125543A,
`respectively.
`
`Ex Vivo Binding Assay
`The nonspecific binding obtained in the presence of 1 ␮M
`rat/human CRF in the ex vivo [125I-Tyr0] ovine CRF binding
`assay averaged 20%. To determine the real proportion of
`CRF1 binding sites in this model, competition studies were
`performed with ovine CRF, antalarmin, SSR125543A, anti-
`sauvagine-30, and rat/human CFR(6 –33) on crude brain and
`pituitary homogenates prepared from untreated rats. As
`shown in Fig. 4A and Table 3, the binding of radiolabeled
`ovine CRF could be competed by ovine CRF with a biphasic
`
`curve, suggesting two populations of 50 and 30% of the total
`binding sites and respective pKi values of 8.35 and 6.23.
`Antalarmin and SSR125543A displaced only the first popu-
`lation of sites in a monophasic manner and similar pKi values
`of 8.80 and 8.89. Antisauvagine-30 competed weakly with
`iodinated ovine CRF with a shallow monophasic curve (pKi ⫽
`6.77, nH ⫽ 0.67). In contrast, the selective CRF-BP ligand
`rat/human CRF(6 –33) inhibited only 30% of the total binding
`that represents the non-CRF1 component. Its low affinity for
`ovine CRF compared with rat/human CRF explains the weak
`pKi (6.43) measured in this study. Unlike crude brain mem-
`branes, the specific binding of [125I-Tyr0] ovine CRF to crude
`rat pituitary homogenates represented 90% of the total bind-
`ing and was completely displaced by 100 nM antalarmin.
`Taking into account the high selectivity of antalarmin, CRF1
`specific binding to crude tissue homogenates was considered
`as the maximal displacement measured in the presence of
`100 nM antalarmin.
`The blockade of brain and pituitary CRF1 receptors was
`evaluated in binding studies performed on crude tissue ho-
`mogenates prepared from rats treated with SSR125543A (ex
`vivo binding assay). No specific CRF1 binding could be mea-
`sured after a 2-h oral treatment at the dose of 30 mg/kg,
`whereas at 4 h postadministration, the binding was still
`reduced by 76 ⫾ 2% (Fig. 4C). The presence of SSR125543A
`at the pituitary level was also demonstrated in the same
`experiment, by a decrease of 67 ⫾ 1% in binding 1 h after
`SSR125543A oral administration that reached 78 ⫾ 1% at 2
`and 4 h (Fig. 4C). Another experiment performed under sim-
`ilar conditions demonstrated that ligand binding inhibition
`was still present 24 h after SSR125543A treatment, with
`62 ⫾ 14% inhibition in the brain and 80 ⫾ 2% in the pituitary
`(mean and S.E.M., n ⫽ 3). Dose-effect study performed 2 h
`after oral treatment revealed a dose-dependent inhibition of
`brain CRF1 receptor binding with an ID50 of 6.5 (3.2–11.8)
`mg/kg (mean and confidence limits; Fig. 4B). SSR125543A
`also reached both brain and pituitary after i.p. injection, ID50
`determined 2 h post-treatment being 11.7 (6.0 –23.0) mg/kg,
`slightly higher than after oral administration (data not
`shown).
`
`CRF1 Receptor Antagonism by SSR125543A: In Vivo
`Studies
`CRF-Induced ACTH Secretion in Rats. In conscious
`rats, the plasma level of ACTH determined by radioimmuno-
`assay was 34 ⫾ 4 pg/ml (mean ⫾ S.E.M., n ⫽ 12). Oral
`administration of 30 mg/kg SSR125543A, 2 h before blood
`sampling significantly diminished the ACTH level (18 ⫾ 2
`pg/ml, p ⬍ 0.01, n ⫽ 5). CRF (4 ␮g/kg i.v.) injection, 30 min
`before blood sampling, induced a more than 10-fold stimula-
`tion (269 ⫾ 20 pg/ml) of the ACTH secretion. When admin-
`istered orally at the dose of 30 mg/kg, SSR125543A inhibited
`the increase in ACTH secretion induced by CRF injection
`with significant effects from 1 to 6 h (Fig. 5A). Dose-effect
`studies performed after oral administration of SSR125543A,
`2 h before the CRF injection, yielded ID50 values of 4.9
`(3.0 – 8.6) mg/kg (Fig. 5B) (means and confident limits). After
`i.v. injection of 3 mg/kg SSR125543A, the maximal inhibition
`of CRF-induced ACTH secretion was observed at 5 min
`postinjection. The dose-effect study performed at the same
`time yielded an ID50 of 1.3 (1.2–1.4) mg/kg i.v. (Fig. 5C).
`
`5
`
`

`

`TABLE 2
`Screening of the selectivity of SSR125543A
`Targets and tissue/cell sources for binding, t

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket